BeOne Medicines Ltd. — Director's Dealing 2022

Jun 24, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2022-06-22

Reporting Person: Yi Qingqing (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-22	Ordinary Shares	A	16692	—	Acquired	24492	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-22	Share Option (Right to Buy)	$11.98	A	34645	Disposed	2032-06-21	Ordinary Shares (34645)	Direct

Footnotes

F1: Represents securities underlying RSUs. All RSUs will vest upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.

F2: The number of securities underlying each option and the exercise price therefor are represented in ordinary shares. Each ADS represents 13 ordinary shares.

F3: The option shall become exercisable in full upon the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the Reporting Person resigns from the board of directors or otherwise ceases to serve as a director, unless the board determines otherwise. Unvested securities are subject to accelerated vesting upon a change in control or certain termination events.